Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Gliosarcoma × depatuxizumab mafodotin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Glioblastoma 5 Neoplasms 2 Brain Neoplasms 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Gliosarcoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 123 Radiotherapy 82 Bevacizumab 41 Radiation 30 Carmustine 26 Irinotecan 21 Erlotinib Hydrochloride 21 Magnetic Resonance Spectroscopy 19 Chemotherapy, Adjuvant 17 Surgical Procedures, Operative 13 O(6)-benzylguanine 13 Carboplatin 13 sargramostim 12 Radiotherapy, Intensity-Modulated 11 Radiotherapy, Conformal 11 Imatinib Mesylate 9 Thalidomide 8 Drug Therapy 8 motexafin gadolinium 7 Radiosurgery 7 Procarbazine 7 Gene Expression Profiling 7 Gefitinib 7 Filgrastim 7 Cyclophosphamide 7 pembrolizumab 6 cediranib 6 Vorinostat 6 Sirolimus 6 Lomustine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02573324 2023-05-11

Intellance1

AbbVie

Phase 3 Completed

691 enrolled 28 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡